ADAPTIN BIO, INC.
Close on Aug 19, 2026
- Market cap
- $55.48M
- P/E (TTM)
- –
- Dividend yield
- –
About Adaptin Bio
Biological Products, (No Diagnostic Substances), SIC 2836
Adaptin Bio, Inc. is a biopharmaceutical company that develops and commercializes therapies designed to enhance the delivery of drugs across physiological barriers, such as the blood-brain barrier, into targeted tissues. Its proprietary technology, including the Brain Bispecific T-cell Engager platform, harnesses the human immune system to transport therapeutics and direct immune cells to destroy tumors. The company's lead product candidate is APTN-101, an epidermal growth factor receptor variant III bispecific T-cell engager engineered to target glioblastoma and other cancers expressing this mutated receptor.
The company operates in the biopharmaceutical sector, progressing its lead candidate through clinical trial regulatory filings, including investigator-initiated single-dose and multi-dose studies accepted by the United States Food and Drug Administration. Its preclinical programs also explore broader applications in central nervous system disorders, autoimmune diseases, and cardiovascular conditions. Adaptin Bio maintains its principal executive offices in Charlotte, North Carolina.
Summary of the business section of Adaptin Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ADAPTIN BIO, INC.
- Founded
- 2022
- Headquarters
- Charlotte, NC
- Address
- 3540 Toringdon Way, Suite 200, #250 28277
- Phone
- (888) 609-1498
- Website
- adaptinbio.com
- Employees
- 4, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, East Brunswick, New Jersey
Stock & identifiers
- Ticker
- APTN
- Exchange
- OTC
- IPO date
- Aug 19, 2026
- Shares outstanding
- 9M, Aug 11, 2026
- Public float
- $9.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1938571
- CUSIP
- 00654M100
- ISIN
- US00654M1009
- EIN
- 88-1566415
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Simon Pedder | Executive Chairman, Director | 928,571 |
| Michael J. Roberts | President and CEO, Director | 2,159,468 |
| L. Arthur Hewitt | Chief Development Officer | – |
| Timothy Maness | Chief Financial Officer | – |
| Anthony P. Zook | Director | – |
| J. Nick Riehle | Director | – |
| Patrick Joseph Gallagher | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had four employees, all of whom are located in the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 1, 2026 | Late filing | Notification of late filing |
| Apr 15, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 31, 2025 | Late filing | Notification of late filing |
| Feb 18, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 18, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 13, 2025 | Name change | Name changed from Unite Acquisition 1 Corp. to ADAPTIN BIO, INC. |